Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
SEC-verified vehicles of the same sponsor, predating these roles and carrying none of them. The badge counts them; the figure beside this one does not.
Mergers closed across all 3 — these vehicles and the franchise's earlier ones together.
Announced but not closed, and still hunting — again over all 3.
No closed vehicle here has both a stored price and a filed trust value to score it against.
2 vehicles on file, newest listing first
3 of 7 appear on more than one
5 people on two or more of them
Dr. Jonathon Kluft is a biotechnology investment professional and life sciences executive who currently serves as a Board Member of JATT II Acquisition Corp. (Nasdaq: JATT), a special purpose acquisition company focused on building the next wave of life sciences companies. He was appointed to the board effective April 16, 2026, concurrent with the company's $60 million IPO priced at $10 per share. His fellow board members include Verender S. Badial, Arjun Goyal, and Christopher Staral, with the board collectively bringing extensive experience across biotechnology. Dr. Kluft holds an indirect interest of 25,000 ordinary shares of JATT II through his membership interests in the company's sponsor entity, JATT Ventures II L.P., as disclosed in his Form 3 filing. These founder shares reflect compensation for his services as a director rather than an open-market transaction.
Dr. Kluft brings more than a decade of experience in biotechnology investing and investment analysis across a broad range of therapeutic areas, with particular expertise in biotech formation and value creation. He currently serves as a Consultant to Atika Capital Management. Previously, he held the role of Vice President of Special Projects and Investments at Roivant Sciences, where he played a key role in the formation of several Roivant subsidiaries, including Immunovant, Urovant, and Pulmovant. At Roivant, he was integral to asset identification, development strategy, and deal structuring for these companies, which have since become notable players in their respective therapeutic domains.
In his capacity as a JATT II director, Dr. Kluft is involved in the SPAC's definitive business combination agreement with Talawar Therapeutics, announced on June 29, 2026. The transaction aims to create a publicly listed biotechnology company developing potentially best-in-class bispecific antibodies for immunology and inflammatory (I&I) diseases, with the combined entity expected to trade on Nasdaq under the ticker "TLWR." The deal is supported by up to $285 million in total proceeds, comprising $60 million from JATT II's trust account and a $225 million oversubscribed PIPE led by Access Biotechnology with participation from Bain Capital Life Sciences, Deep Track Capital, RA Capital Management, Janus Henderson Investors, and other leading healthcare investors. The combined company's lead asset, TALA-125, a novel anti-IL-13 × anti-IL-18 bispecific antibody for atopic dermatitis, is expected to enter the clinic in the first quarter of 2027.
Dr. Kluft is based in Westfield, New Jersey 07091. His professional network within JATT II includes fellow board members Christopher Staral, Verender S. Badial, and Arjun Goyal. His ownership reports on file with the SEC indicate that JATT II Acquisition Corp. is the only public company in which he holds a reported director-level position. No additional details regarding his educational background or earlier career history prior to his tenure at Roivant Sciences were available in the sources reviewed.
This record is keyed to SEC CIK 0002128326 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 9 institutional-holder rows on these vehicles, under 7 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.